128.75
前日終値:
$136.55
開ける:
$136.16
24時間の取引高:
886.73K
Relative Volume:
1.01
時価総額:
$8.33B
収益:
$74.06M
当期純損益:
$-114.71M
株価収益率:
-71.37
EPS:
-1.8039
ネットキャッシュフロー:
$-117.90M
1週間 パフォーマンス:
-10.42%
1か月 パフォーマンス:
-9.86%
6か月 パフォーマンス:
+24.12%
1年 パフォーマンス:
+70.01%
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
名前
Protagonist Therapeutics Inc
セクター
電話
(510) 474-0170
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
PTGX
Protagonist Therapeutics Inc
|
128.75 | 8.33B | 74.06M | -114.71M | -117.90M | -1.8039 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-12 | 開始されました | UBS | Buy |
| 2026-08-10 | アップグレード | Goldman | Neutral → Buy |
| 2026-05-21 | 開始されました | Wolfe Research | Outperform |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-12 | 開始されました | Leerink Partners | Outperform |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-12-06 | 開始されました | Goldman | Neutral |
| 2024-11-05 | 開始されました | Wedbush | Outperform |
| 2024-09-24 | 開始されました | TD Cowen | Buy |
| 2024-09-09 | 開始されました | Truist | Buy |
| 2023-10-30 | 開始されました | CapitalOne | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-11 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-24 | 開始されました | Northland Capital | Outperform |
| 2021-01-06 | 開始されました | JP Morgan | Overweight |
| 2020-12-16 | 開始されました | Piper Sandler | Overweight |
| 2020-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | 開始されました | Jefferies | Buy |
| 2020-05-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-09 | アップグレード | Stifel | Hold → Buy |
| 2018-12-06 | 開始されました | Nomura | Buy |
| 2018-01-29 | 開始されました | Stifel | Buy |
| 2017-07-21 | 開始されました | BTIG Research | Buy |
すべてを表示
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know - Zacks Investment Research
Protagonist Therapeutics (PTGX) Could Be 21% Undervalued As Royalty Funded Narrative Builds - Simply Wall Street
Protagonist Therapeutics (NASDAQ:PTGX) Raised to "Strong-Buy" at UBS Group - MarketBeat
UBS sets USD 184.00 target for Protagonist Therapeutics stock - ad-hoc-news.de
UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target - Moomoo
Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology - Seeking Alpha
Protagonist Therapeutics (NASDAQ:PTGX) Stock Keeps "Outperform" Rating at Leerink Partners - MarketBeat
UBS initiates Protagonist Therapeutics stock with buy rating on drug potential - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Cut to "Buy" at Wall Street Zen - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock forecasts - Yahoo Finance UK
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance
Protagonist Therapeutics, Inc. (PTGX) Options Chain - Yahoo! Finance Canada
Protagonist Therapeutics, Inc. (PTGX) Options Chain - Yahoo! Finance Canada
Protagonist Therapeutics, Inc. (PTGX) options chain - Yahoo Finance Australia
Protagonist Therapeutics(PTGX.US) Officer Sells US$8.31 Million in Common Stock - Moomoo
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells 58,629 Shares of Company Stock - MarketBeat
After exercising options, Protagonist Therapeutics (PTGX) CFO sells 58,629 shares under a trading plan. - stocktitan.net
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Has Consensus Price Target of $147.13 According to Analysts - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance
Form 144 PROTAGONIST THERAPEUTICS For: 1 October By Investing.com - Investing.com Nigeria
Officer Asif Ali plans to sell 58,629 Protagonist Therapeutics (PTGX) shares. - Stock Titan
Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today - Benzinga
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap UpWhat's Next? - MarketBeat
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Protagonist Therapeutics (Nasdaq:PTGX)Stock Analysis - simplywall.st
1,324,498 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Bank of America Corp DE - MarketBeat
PTGX: Protagonist Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Protagonist Therapeutics (NASDAQ:PTGX) Combines High Growth Momentum With a Breakout Setup - ChartMill
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 11,200 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Protagonist Therapeutics CEO sells $18.2m in shares By Investing.com - Investing.com Australia
Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing - Yahoo Finance
Dinesh Ph Patel Sells 63,548 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 54,174 Shares - MarketBeat
Protagonist Therapeutics CEO sells $18.2m in shares - Investing.com India
Protagonist Therapeutics CEO sells $18.2m in shares By Investing.com - Investing.com UK
Protagonist Therapeutics (PTGX) CEO sells 125K shares in preset plan - Stock Titan
Protagonist Therapeutics(PTGX.US) Officer Sells US$18.24 Million in Common Stock - Moomoo
Protagonist Therapeutics at Cantor conference: cash, launches and pipeline By Investing.com - Investing.com Nigeria
Protagonist Therapeutics at Cantor conference: cash, launches and pipeline By Investing.com - Investing.com UK
Protagonist Therapeutics, Inc. at Citi Biopharma Back to School Summit Transcript - GuruFocus
Transcript : Protagonist Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Protagonist Therapeutics authorizes $300 million buyback plan By Investing.com - Investing.com Nigeria
Protagonist Therapeutics authorizes $300 million buyback plan By Investing.com - Investing.com South Africa
Protagonist Therapeutics (PTGX) CEO gifts stock to family - Stock Titan
Protagonist Therapeutics authorizes $300 million buyback plan - investing.com
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - ACCESS Newswire
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - chronicle-tribune.com
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - marketscreener.com
Protagonist Therapeutics Inc (PTGX) 財務データ
収益
当期純利益
現金流量
EPS
Protagonist Therapeutics Inc (PTGX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ASIF ALI | Officer |
Sep 30 '26 |
Proposed Sale |
140.97 |
58,629 |
8,264,930 |
0 |
| Ali Asif | Chief Financial Officer |
Sep 30 '26 |
Sale |
141.78 |
58,629 |
8,312,294 |
59,003 |
| PATEL DINESH V PH D | President and CEO |
Sep 10 '26 |
Sale |
144.10 |
7,278 |
1,048,760 |
522,968 |
| PATEL DINESH V PH D | President and CEO |
Sep 10 '26 |
Option Exercise |
21.58 |
7,278 |
157,059 |
530,246 |
| PATEL DINESH V PH D | President and CEO |
Sep 09 '26 |
Option Exercise |
21.58 |
63,548 |
1,371,366 |
586,516 |
| PATEL DINESH V PH D | President and CEO |
Sep 09 '26 |
Sale |
146.18 |
63,548 |
9,289,447 |
522,968 |
| PATEL DINESH V PH D | President and CEO |
Sep 08 '26 |
Sale |
145.87 |
54,174 |
7,902,361 |
522,968 |
| PATEL DINESH V PH D | President and CEO |
Sep 08 '26 |
Option Exercise |
21.58 |
54,174 |
1,169,075 |
577,142 |
| PATEL DINESH V PH D | President and CEO |
Aug 11 '26 |
Sale |
148.52 |
34,239 |
5,085,176 |
523,478 |
| PATEL DINESH V PH D | President and CEO |
Aug 11 '26 |
Option Exercise |
21.58 |
34,239 |
738,878 |
557,717 |
大文字化:
|
ボリューム (24 時間):